Literature DB >> 16855496

Review of patients with basal cell nevus syndrome.

Simon F Taylor1, Anne E Cook, Brian Leatherbarrow.   

Abstract

PURPOSE: To review patients with basal cell nevus syndrome (BCNS), documenting presentation, referrals, treatment patterns, and associated morbidity.
METHODS: Cross-sectional review and retrospective data collection of 39 patients with BCNS. Patients from the BCNS support group were invited to be examined. Demographics, presenting features, associated pathologies, and treatment modalities were recorded. Demographic data, age at presentation, age at diagnosis, spectrum of ophthalmic and periocular disease, treatment modalities used, and periocular deformities developed were reviewed.
RESULTS: Thirty-nine patients were included with age range of 5 to 72 years. Presenting clinical features included odontogenic keratocyst in 17 patients and basal cell carcinoma in 13 patients; less common presentations were with congenital malformations (n = 2), with ophthalmic associations (n = 3), and at genetic counseling (n = 4). Seventeen of the 39 patients confirmed a parental diagnosis of BCNS. Basal cell carcinoma developed in 18 of the 28 patients before the age of 30, confirming the reported early age of onset. Periocular basal cell carcinoma was reported in 24 of 39 patients (61%), with recurrent disease reported in 17 of these 24 (71%), despite a variety of treatment modalities used. Associated ophthalmic features were multiple eyelid cysts (15 patients), strabismus (9 patients), myopia (5 patients), hyperopia (7 patients), cataracts (5 patients), myelinated nerve fibers (3 patients), amblyopia (3 patients), and nystagmus and iris transillumination defects (2 patients each). All patients were involved in multidisciplinary medical care.
CONCLUSIONS: Patients with BCNS frequently have ophthalmic manifestations, particularly periocular basal cell carcinoma. Multidisciplinary care is essential in the care of the patient with BCNS. Early diagnosis of BCNS may allow for skin protection and surveillance at an earlier age.

Entities:  

Mesh:

Year:  2006        PMID: 16855496     DOI: 10.1097/01.iop.0000225421.60264.68

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  7 in total

1.  Activation of the hedgehog signaling pathway in the developing lens stimulates ectopic FoxE3 expression and disruption in fiber cell differentiation.

Authors:  Christine L Kerr; Jian Huang; Trevor Williams; Judith A West-Mays
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-05       Impact factor: 4.799

Review 2.  Genetics of anophthalmia and microphthalmia. Part 2: Syndromes associated with anophthalmia-microphthalmia.

Authors:  Anne Slavotinek
Journal:  Hum Genet       Date:  2018-10-30       Impact factor: 4.132

3.  Bilateral ovarian fibroma associated with Gorlin syndrome.

Authors:  Shahnaz Aram; Noushin Afshar Moghaddam
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

Review 4.  Review of Ocular Manifestations of Nevoid Basal Cell Carcinoma Syndrome: What an Ophthalmologist Needs to Know.

Authors:  Judy J Chen; Juliana Sartori; Vinay K Aakalu; Pete Setabutr
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec

5.  A role for smoothened during murine lens and cornea development.

Authors:  Janet J Y Choi; Chao-Tung Ting; Lidia Trogrlic; Stefan V Milevski; Mary Familari; Gemma Martinez; Robb U de Iongh
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

6.  Ocular manifestations in Gorlin-Goltz syndrome.

Authors:  Antonietta Moramarco; Ehud Himmelblau; Emanuele Miraglia; Fabiana Mallone; Vincenzo Roberti; Federica Franzone; Chiara Iacovino; Sandra Giustini; Alessandro Lambiase
Journal:  Orphanet J Rare Dis       Date:  2019-09-18       Impact factor: 4.123

7.  Neonatal Onset Glaucoma in a Case with Gorlin-Goltz Syndrome: An Unusual Association.

Authors:  A B Tefon Arıbaş; Zeynep Aktaş; Şengül Özdek
Journal:  J Curr Glaucoma Pract       Date:  2021 May-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.